| ND: |
ME10806048 |
| PMID: |
10806048 |
| LR: |
20061115 |
| CED: |
20000803 |
| DCO: |
20000803 |
| Autoren: |
Piperno M; Reboul P; Hellio Le Graverand MP; Peschard MJ; Annefeld M; Richard M; Vignon E |
| Titel: |
Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. |
| Quelle: |
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society; VOL: 8 (3); p. 207-12 /200005/ |
| PM: |
Print |
| SU: |
IM |
| Sprache: |
English |
| CY: |
ENGLAND |
| JID: |
9305697 |
| ISSN: |
1063-4584 |
| Institution: |
Centre Hospitalier Lyon Sud, Claude Bernard University, 165 chemin du Grand Revoyet, Pierre Bénite, France. |
| DT: |
Journal Article; Research Support, Non-U.S. Gov't |
| Schlagwörter |
| CT: |
CASEINS/drug effects; CELLS, CULTURED; CHONDROCYTES/*drug effects; COLLAGENASES/drug effects; CULTURE MEDIA; CYCLIC AMP/metabolism; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSAMINE/*pharmacology; HUMANS; NITRIC OXIDE/metabolism; OSTEOARTHRITIS/*metabolism; PHOSPHOLIPASES A/drug effects; PROTEIN BIOSYNTHESIS; PROTEIN KINASE C/drug effects |
| CTG: |
CASEINE/Arzneimittelwirkungen; ZELLEN, KULTIVIERTE; CHONDROZYTEN/*Arzneimittelwirkungen; KOLLAGENASEN/Arzneimittelwirkungen; KULTURMEDIEN; CYCLO-AMP/Stoffwechsel; DOSIS-WIRKUNGSBEZIEHUNG, ARZNEIMITTEL-; GLUCOSAMIN/*Pharmakologie; MENSCH; STICKSTOFFMONOXID/Stoffwechsel; OSTEOARTHROSE/*Stoffwechsel; PHOSPHOLIPASEN A/Arzneimittelwirkungen; PROTEINBIOSYNTHESE; PROTEIN-KINASE C/Arzneimittelwirkungen |
| TE: |
Caseins; Culture Media; Nitric Oxide/10102-43-9; Glucosamine/3416-24-8; Cyclic AMP/60-92-4; Protein Kinase C/E.C. 2.7.1.37; Phospholipases A/E.C. 3.1.1.-; Collagenases/E.C. 3.4.24.- |
| CR: |
10102-43-9; 3416-24-8; 60-92-4; E.C. 2.7.1.37; E.C. 3.1.1.-; E.C. 3.4.24.- |
| AB: |
OBJECTIVE: The efficacy of glucosamine sulfate (GS) in the symptomatic treatment of patients with osteoarthritis (OA) is suggested to be mediated by still unknown effects on the altered OA cartilage. DESIGN: Using human OA chondrocytes in culture, the effects of GS on protein synthesis, caseinase, collagenase, phospholipase A2 (PLA2) and protein kinase C (PKC) activities as well as production of nitric oxide and cyclic AMP were studied in both cells and culture medium. RESULTS: GS significantly reduced PLA2 activity, and more modestly collagenase activity, in the OA chondrocytes in a dose-dependent manner. By contrast, PLA2 and collagenase activity of the culture medium was not modified. No effects on caseinase activity was seen. GS significantly and dose-dependently increased protein synthesis. GS did not modify nitric oxide and cAMP production but significantly increased PKC production. CONCLUSION: GS modified cultured OA chondrocyte metabolism by acting on PKC, cellular PLA2, protein synthesis and possibly collagenase activation. Extrapolation of the effect to the in-vivo situation remains hypothetical but they might represent some possible mechanisms of action of the drug in human. |